{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:50:10Z","timestamp":1793407810070,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":121,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01685-5","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:06:36Z","timestamp":1780999596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploratory associations between co-occurring opioid and alcohol use disorders and GIP\/GLP-1 receptor agonist treatment"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-220X","authenticated-orcid":false,"given":"Fares","family":"Qeadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlie","family":"McCunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tingey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-5884","authenticated-orcid":false,"given":"Philip J.","family":"Kroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"1685_CR1","doi-asserted-by":"crossref","unstructured":"Esser, M. B., Sherk, A., Liu, Y. & Naimi, T. S. Deaths from excessive alcohol use\u2014United States, 2016\u20132021. MMWR Morb. Mortal. Wkly. Rep. 73, (2024).","DOI":"10.15585\/mmwr.mm7308a1"},{"key":"1685_CR2","unstructured":"National Institute on Drug Abuse. Drug Overdose Deaths: Facts and Figures. National Institutes of Health https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates#Fig3 (2024)."},{"key":"1685_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108886","volume":"226","author":"CM Mintz","year":"2021","unstructured":"Mintz, C. M. et al. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. Drug Alcohol Depend. 226, 108886 (2021).","journal-title":"Drug Alcohol Depend."},{"key":"1685_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104434","volume":"128","author":"T Santo Jr","year":"2024","unstructured":"Santo Jr, T. et al. Prevalence of comorbid substance use disorders among people with opioid use disorder: a systematic review & meta-analysis. Int. J. Drug Policy 128, 104434 (2024).","journal-title":"Int. J. Drug Policy"},{"key":"1685_CR5","doi-asserted-by":"publisher","first-page":"e210061","DOI":"10.1001\/jamanetworkopen.2021.0061","volume":"4","author":"KY Xu","year":"2021","unstructured":"Xu, K. Y. et al. Association of opioid use disorder treatment with alcohol-related acute events. JAMA Netw. Open 4, e210061\u2013e210061 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/acer.13594","volume":"42","author":"K Witkiewitz","year":"2018","unstructured":"Witkiewitz, K. & Vowles, K. E. Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review. Alcohol. Clin. Exp. Res. 42, 478\u2013488 (2018).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1685_CR7","first-page":"718","volume":"23","author":"PB Landsman-Blumberg","year":"2017","unstructured":"Landsman-Blumberg, P. B. et al. Burden of alcohol abuse or dependence among long-term opioid users with chronic noncancer pain. J. Manag. Care Spec. Pharm. 23, 718\u2013724 (2017).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"1685_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108555","volume":"221","author":"P O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, P., Henke, R. M., Schaefer, M. B., Lin, J. & Creedon, T. B. Adverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disorders. Drug Alcohol Depend. 221, 108555 (2021).","journal-title":"Drug Alcohol Depend."},{"key":"1685_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s40429-017-0147-x","volume":"4","author":"KA Edwards","year":"2017","unstructured":"Edwards, K. A., Vowles, K. E. & Witkiewitz, K. Co-use of alcohol and opioids. Curr. Addict. Rep. 4, 194\u2013199 (2017).","journal-title":"Curr. Addict. Rep."},{"key":"1685_CR10","volume":"2015","author":"J Lee","year":"2015","unstructured":"Lee, J., Kresina, T. F., Campopiano, M., Lubran, R. & Clark, H. W. Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care. BioMed. Res. Int. 2015, 137020 (2015).","journal-title":"BioMed. Res. Int."},{"key":"1685_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/02791072.2022.2073300","volume":"55","author":"SK Kedia","year":"2023","unstructured":"Kedia, S. K. et al. Efficacy of extended-release injectable naltrexone on alcohol use disorder treatment: a systematic review. J. Psychoact. Drugs 55, 233\u2013245 (2023).","journal-title":"J. Psychoact. Drugs"},{"key":"1685_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-015-0423-9","volume":"75","author":"GL Plosker","year":"2015","unstructured":"Plosker, G. L. Acamprosate: a review of its use in alcohol dependence. Drugs 75, 1255\u20131268 (2015).","journal-title":"Drugs"},{"key":"1685_CR13","doi-asserted-by":"publisher","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","volume":"9","author":"MD Skinner","year":"2014","unstructured":"Skinner, M. D., Lahmek, P., Pham, H. & Aubin, H.-J. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS ONE 9, e87366 (2014).","journal-title":"PLoS ONE"},{"key":"1685_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/TCRM.S23184","volume":"8","author":"K Witkiewitz","year":"2012","unstructured":"Witkiewitz, K., Saville, K. & Hamreus, K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther. Clin. Risk Manag. 8, 45\u201353 (2012).","journal-title":"Ther. Clin. Risk Manag."},{"key":"1685_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7326\/M15-2771","volume":"165","author":"PO Coffin","year":"2016","unstructured":"Coffin, P. O. et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann. Intern Med. 165, 245\u2013252 (2016).","journal-title":"Ann. Intern Med"},{"key":"1685_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/add.13265","volume":"111","author":"SM Bird","year":"2016","unstructured":"Bird, S. M., McAuley, A., Perry, S. & Hunter, C. Effectiveness of Scotland\u2019s National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. Addiction 111, 883\u2013891 (2016).","journal-title":"Addiction"},{"key":"1685_CR17","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives Ch. 2 (National Academies Press, 2019)."},{"key":"1685_CR18","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59, Center for Behavioral Health Statistics and Quality, 2024)."},{"key":"1685_CR19","doi-asserted-by":"crossref","unstructured":"Blevins, C. E., Rawat, N. & Stein, M. D. Gaps in the substance use disorder treatment referral process: provider perceptions. J. Addict. Med. 12, 273\u2013277 (2018).","DOI":"10.1097\/ADM.0000000000000400"},{"key":"1685_CR20","doi-asserted-by":"crossref","unstructured":"Farhoudian, A. et al. Barriers and facilitators to substance use disorder treatment: an overview of systematic reviews. Subst. Abuse Res. Treat. 16, 11782218221118462 (2022).","DOI":"10.1177\/11782218221118462"},{"key":"1685_CR21","doi-asserted-by":"publisher","first-page":"e2241128","DOI":"10.1001\/jamanetworkopen.2022.41128","volume":"5","author":"JH Cantor","year":"2022","unstructured":"Cantor, J. H. et al. Patterns in geographic distribution of substance use disorder treatment facilities in the US and accepted forms of payment from 2010 to 2021. JAMA Netw. Open 5, e2241128\u2013e2241128 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR22","doi-asserted-by":"crossref","unstructured":"Barnett, E. R., Knight, E., Herman, R. J., Amarakaran, K. & Jankowski, M. K. Difficult binds: a systematic review of facilitators and barriers to treatment among mothers with substance use disorders. J. Subst. Abuse Treat. 126, 108341 (2021).","DOI":"10.1016\/j.jsat.2021.108341"},{"key":"1685_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/add.15116","volume":"116","author":"LA Lin","year":"2021","unstructured":"Lin, L. A. et al. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction 116, 96\u2013104 (2021).","journal-title":"Addiction"},{"key":"1685_CR24","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/add.13339","volume":"111","author":"KS Betts","year":"2016","unstructured":"Betts, K. S. et al. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies. Addiction 111, 1214\u20131223 (2016).","journal-title":"Addiction"},{"key":"1685_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","volume":"95","author":"H Samples","year":"2018","unstructured":"Samples, H., Williams, A. R., Olfson, M. & Crystal, S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J. Subst. Abus. Treat. 95, 9\u201317 (2018).","journal-title":"J. Subst. Abus. Treat."},{"key":"1685_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109624","volume":"240","author":"Z Cui","year":"2022","unstructured":"Cui, Z. et al. Predictors of crystal methamphetamine use initiation or re-initiation among people receiving opioid agonist therapy: a prospective cohort study. Drug Alcohol Depend. 240, 109624 (2022).","journal-title":"Drug Alcohol Depend."},{"key":"1685_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13311-019-00814-4","volume":"17","author":"AJ Abraham","year":"2020","unstructured":"Abraham, A. J., Andrews, C. M., Harris, S. J. & Friedmann, P. D. Availability of medications for the treatment of alcohol and opioid use disorder in the USA. Neurotherapeutics 17, 55\u201369 (2020).","journal-title":"Neurotherapeutics"},{"key":"1685_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72\u2013130 (2019).","journal-title":"Mol. Metab."},{"key":"1685_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/add.16679","volume":"120","author":"F Qeadan","year":"2025","unstructured":"Qeadan, F., McCunn, A. & Tingey, B. The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis. Addiction 120, 236\u2013250 (2025).","journal-title":"Addiction"},{"key":"1685_CR30","doi-asserted-by":"publisher","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","volume":"7","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder. JAMA Netw. Open 7, e2435247\u2013e2435247 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat. Commun. 15, 4548 (2024).","journal-title":"Nat. Commun."},{"key":"1685_CR32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/M23-2718","volume":"177","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Association of semaglutide with tobacco use disorder in patients with type 2 diabetes. Ann. Intern. Med. 177, 1016\u20131027 (2024).","journal-title":"Ann. Intern. Med."},{"key":"1685_CR33","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","volume":"29","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol. Psychiatry 29, 2587\u20132598 (2024).","journal-title":"Mol. Psychiatry"},{"key":"1685_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/add.16626","volume":"120","author":"ND Volkow","year":"2025","unstructured":"Volkow, N. D. & Xu, R. GLP-1R agonist medications for addiction treatment. Addiction 120, 198\u2013200 (2025).","journal-title":"Addiction"},{"key":"1685_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","volume":"179","author":"MK Klausen","year":"2022","unstructured":"Klausen, M. K., Thomsen, M., Wortwein, G. & Fink-Jensen, A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br. J. Pharm. 179, 625\u2013641 (2022).","journal-title":"Br. J. Pharm."},{"key":"1685_CR36","doi-asserted-by":"crossref","unstructured":"Richards, J. R. et al. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series. J. Clin. Psychiatry 85, 23m15068 (2023).","DOI":"10.4088\/JCP.23m15068"},{"key":"1685_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot, C. S. et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 82, 395\u2013405 (2025).","journal-title":"JAMA Psychiatry"},{"key":"1685_CR38","doi-asserted-by":"crossref","unstructured":"Klausen, M. K. et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 7, e159863 (2022).","DOI":"10.1172\/jci.insight.159863"},{"key":"1685_CR39","doi-asserted-by":"publisher","first-page":"e2213014","DOI":"10.1001\/jamanetworkopen.2022.13014","volume":"5","author":"AGL Vannier","year":"2022","unstructured":"Vannier, A. G. L. et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw. Open 5, e2213014\u2013e2213014 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","volume":"34","author":"LD Tyson","year":"2022","unstructured":"Tyson, L. D. et al. Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. Eur. J. Gastroenterol. Hepatol. 34, 567\u2013575 (2022).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1685_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L. & Lucey, M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the american association for the study of liver diseases. Hepatology 71, 306\u2013333 (2020).","journal-title":"Hepatology"},{"key":"1685_CR42","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","volume":"20","author":"J Chick","year":"1999","unstructured":"Chick, J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 20, 427\u2013435 (1999).","journal-title":"Drug Saf."},{"key":"1685_CR43","doi-asserted-by":"crossref","unstructured":"Laks, J. & Alford, D. P. Treatment of opioid use disorder in patients with liver disease. Clin. Liver Dis. 23, e0207 (2024).","DOI":"10.1097\/CLD.0000000000000207"},{"key":"1685_CR44","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/hep4.2080","volume":"6","author":"D Ayyala","year":"2022","unstructured":"Ayyala, D. et al. Naltrexone for alcohol use disorder: hepatic safety in patients with and without liver disease. Hepatol. Commun. 6, 3433\u20133442 (2022).","journal-title":"Hepatol. Commun."},{"key":"1685_CR45","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med 384, 1113\u20131124 (2021).","journal-title":"N. Engl. J. Med"},{"key":"1685_CR46","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","volume":"30","author":"A Singh","year":"2024","unstructured":"Singh, A., Sohal, A. & Batta, A. GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J. Gastroenterol. 30, 5205\u20135211 (2024).","journal-title":"World J. Gastroenterol."},{"key":"1685_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","volume":"8","author":"G Targher","year":"2023","unstructured":"Targher, G., Mantovani, A. & Byrne, C. D. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.  Lancet Gastroenterol. Hepatol. 8, 179\u2013191 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1685_CR48","doi-asserted-by":"publisher","first-page":"108120","DOI":"10.1016\/j.dib.2022.108120","volume":"42","author":"L Ehwerhemuepha","year":"2022","unstructured":"Ehwerhemuepha, L. et al. Cerner real-world data (CRWD) - a de-identified multicenter electronic health records database. Data Brief. 42, 108120 (2022).","journal-title":"Data Brief."},{"key":"1685_CR49","unstructured":"Chronic Conditions Data Warehouse. Other Chronic Health, Mental Health, and Potentially Disabling Chronic Conditions Algorithms: MBSF_OTCC_{YYYY} File. https:\/\/www2.ccwdata.org\/documents\/10280\/19139421\/other-condition-algorithms.pdf (2024)."},{"key":"1685_CR50","unstructured":"Biopharma P. E. G. Evolution of GLP-1 receptor agonists for diabetes treatment. https:\/\/www.biochempeg.com\/article\/299.html (2022)."},{"key":"1685_CR51","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.  Lancet 370, 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"1685_CR52","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/add.16632","volume":"119","author":"D Eide","year":"2024","unstructured":"Eide, D. et al. Heightened mortality risk after a non-fatal opioid overdose: risk factors for mortality in the week following emergency treatment. Addiction 119, 2131\u20132138 (2024).","journal-title":"Addiction"},{"key":"1685_CR53","doi-asserted-by":"crossref","unstructured":"Hartung, D. M. et al. Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data. J. Subst. Use Addict. Treat. 147, 208971 (2023).","DOI":"10.1016\/j.josat.2023.208971"},{"key":"1685_CR54","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1007\/s11606-022-08014-1","volume":"38","author":"JR Lyden","year":"2023","unstructured":"Lyden, J. R., Xu, S., Narwaney, K. J., Glanz, J. M. & Binswanger, I. A. Opioid overdose risk following hospital discharge among individuals prescribed long-term opioid therapy: a risk interval analysis. J. Gen. Intern. Med. 38, 2560\u20132567 (2023).","journal-title":"J. Gen. Intern. Med."},{"key":"1685_CR55","doi-asserted-by":"publisher","first-page":"109472","DOI":"10.1016\/j.drugalcdep.2022.109472","volume":"236","author":"S Goldman-Mellor","year":"2022","unstructured":"Goldman-Mellor, S., Olfson, M. & Schoenbaum, M. Acute injury mortality and all-cause mortality following emergency department presentation for alcohol use disorder. Drug Alcohol Depend. 236, 109472 (2022).","journal-title":"Drug Alcohol Depend."},{"key":"1685_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"key":"1685_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T. & Chou, R. CDC clinical practice guideline for prescribing opioids for pain-United States, 2022. MMWR Recomm. Rep. 71, 1\u201395 (2022).","journal-title":"MMWR Recomm. Rep."},{"key":"1685_CR58","doi-asserted-by":"publisher","first-page":"e1004123","DOI":"10.1371\/journal.pmed.1004123","volume":"19","author":"MC Kennedy","year":"2022","unstructured":"Kennedy, M. C. et al. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: a retrospective cohort study. PLOS Med. 19, e1004123 (2022).","journal-title":"PLOS Med."},{"key":"1685_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/pds.4372","volume":"27","author":"L Pazzagli","year":"2018","unstructured":"Pazzagli, L. et al. Methods for time-varying exposure related problems in pharmacoepidemiology: an overview. Pharmacoepidemiol. Drug Saf. 27, 148\u2013160 (2018).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1685_CR60","doi-asserted-by":"crossref","unstructured":"Robins J. M., Hern\u00e1n M\u00c1, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 11, 550\u2013560 (2000).","DOI":"10.1097\/00001648-200009000-00011"},{"key":"1685_CR61","doi-asserted-by":"publisher","first-page":"583","DOI":"10.29220\/CSAM.2017.24.6.583","volume":"24","author":"Y Xue","year":"2017","unstructured":"Xue, Y. & Schifano, E. D. Diagnostics for the Cox model. CSAM 24, 583\u2013604 (2017).","journal-title":"CSAM"},{"key":"1685_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld, D. Partial residuals for the proportional hazards regression model. Biometrika 69, 239\u2013241 (1982).","journal-title":"Biometrika"},{"key":"1685_CR63","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1007\/s11999-008-0346-9","volume":"466","author":"DJ Biau","year":"2008","unstructured":"Biau, D. J., Kern\u00e9is, S. & Porcher, R. Statistics in brief: the importance of sample size in the planning and interpretation of medical research. Clin. Orthop. Relat. Res. 466, 2282\u20132288 (2008).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"1685_CR64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jpainsymman.2015.08.003","volume":"51","author":"JH Flory","year":"2016","unstructured":"Flory, J. H., Wiesenthal, A. C., Thaler, H. T., Koranteng, L. & Moryl, N. Methadone use and the risk of hypoglycemia for inpatients with cancer pain. J. Pain. Symptom. Manag. 51, 79\u201387.e1 (2016).","journal-title":"J. Pain. Symptom. Manag."},{"key":"1685_CR65","unstructured":"Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf (2022)."},{"key":"1685_CR66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/00220426231204841","volume":"55","author":"M Hutchison","year":"2025","unstructured":"Hutchison, M. et al. Trends and barriers of medication treatment for opioid use disorders: a systematic review and meta-analysis. J. Drug Issues 55, 193\u2013214 (2025).","journal-title":"J. Drug Issues"},{"key":"1685_CR67","doi-asserted-by":"crossref","unstructured":"Liao S., Jang S., Tharp J. A., Lester N. A. Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset. J. Subst. Use Addict. Treat. 154, 209139 (2023).","DOI":"10.1016\/j.josat.2023.209139"},{"key":"1685_CR68","doi-asserted-by":"publisher","first-page":"e2029676","DOI":"10.1001\/jamanetworkopen.2020.29676","volume":"3","author":"JR Morgan","year":"2020","unstructured":"Morgan, J. R. et al. Comparison of rates of overdose and hospitalization after initiation of medication for opioid use disorder in the inpatient vs outpatient setting. JAMA Netw. Open 3, e2029676\u2013e2029676 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR69","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.dadr.2022.100114","volume":"5","author":"BP O\u2019Rourke","year":"2022","unstructured":"O\u2019Rourke, B. P. et al. Initiation of medication for opioid use disorder across a health system: a retrospective analysis of patient characteristics and inpatient outcomes. Drug Alcohol Depend. Rep. 5, 100114 (2022).","journal-title":"Drug Alcohol Depend. Rep."},{"key":"1685_CR70","doi-asserted-by":"publisher","first-page":"e2447644","DOI":"10.1001\/jamanetworkopen.2024.47644","volume":"7","author":"LR Miller-Matero","year":"2024","unstructured":"Miller-Matero, L. R. et al. Alcohol use and antiobesity medication treatment. JAMA Netw. Open 7, e2447644\u2013e2447644 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR71","doi-asserted-by":"crossref","unstructured":"Draghmeh K., Fuehrlein B. Emerging therapeutics in the treatment of substance use disorders: a focus on GLP-1 receptor agonists, D3R antagonists, and CRF antagonists. J. Integr. Neurosci. 24, 26361 (2025).","DOI":"10.31083\/JIN26361"},{"key":"1685_CR72","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman, S. E. et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw. Open 3, e1920622\u2013e1920622 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR73","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters, M. et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA 330, 1653\u20131665 (2023).","journal-title":"JAMA"},{"key":"1685_CR74","doi-asserted-by":"publisher","first-page":"111067","DOI":"10.1016\/j.drugalcdep.2023.111067","volume":"255","author":"PS Michener","year":"2024","unstructured":"Michener, P. S., Knee, A., Wilson, D., Boama-Nyarko, E. & Friedmann, P. D. Association of random and observed urine drug screening with long-term retention in opioid treatment programs. Drug Alcohol Depend. 255, 111067 (2024).","journal-title":"Drug Alcohol Depend."},{"key":"1685_CR75","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740\u2013756 (2018).","journal-title":"Cell Metab."},{"key":"1685_CR76","doi-asserted-by":"crossref","unstructured":"Van Hale, C. & Gluck, R. Laboratory monitoring for patients on buprenorphine: 10 questions. Curr. Psychiatry 21, 9 (2022).","DOI":"10.12788\/cp.0282"},{"key":"1685_CR77","unstructured":"Kumar, R., Viswanath, O. & Saadabadi, A. Buprenorphine. In StatPearls (StatPearls Publishing, 2024)."},{"key":"1685_CR78","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Buprenorphine. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (National Institute of Diabetes and Digestive and Kidney Diseases, 2012)."},{"key":"1685_CR79","doi-asserted-by":"crossref","unstructured":"Selby, P. J. et al. Chapter 6: How can monitoring impact on patient outcomes? In Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT (NIHR Journals Library, 2018).","DOI":"10.3310\/pgfar06030"},{"key":"1685_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7570\/jomes22021","volume":"31","author":"Y Huh","year":"2022","unstructured":"Huh, Y., Cho, Y. J. & Nam, G. E. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. J. Obes. Metab. Syndr. 31, 17\u201327 (2022).","journal-title":"J. Obes. Metab. Syndr."},{"key":"1685_CR81","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1210\/en.2011-1443","volume":"153","author":"AL Alhadeff","year":"2012","unstructured":"Alhadeff, A. L., Rupprecht, L. E. & Hayes, M. R. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153, 647\u2013658 (2012).","journal-title":"Endocrinology"},{"key":"1685_CR82","doi-asserted-by":"crossref","unstructured":"Adinoff, B. Neurobiologic processes in drug reward and addiction. Harv. Rev. Psychiatry 12, 305\u2013320 (2004).","DOI":"10.1080\/10673220490910844"},{"key":"1685_CR83","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrn.2017.130","volume":"18","author":"ND Volkow","year":"2017","unstructured":"Volkow, N. D., Wise, R. A. & Baler, R. The dopamine motive system: implications for drug and food addiction. Nat. Rev. Neurosci. 18, 741\u2013752 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"1685_CR84","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrn3105","volume":"12","author":"PJ Kenny","year":"2011","unstructured":"Kenny, P. J. Common cellular and molecular mechanisms in obesity and drug addiction. Nat. Rev. Neurosci. 12, 638\u2013651 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"1685_CR85","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","volume":"32","author":"SL Dickson","year":"2012","unstructured":"Dickson, S. L. et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 32, 4812\u20134820 (2012).","journal-title":"J. Neurosci."},{"key":"1685_CR86","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/DMSO.S387116","volume":"16","author":"M Aldawsari","year":"2023","unstructured":"Aldawsari, M. et al. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diab Metab. Syndr. Obes. 16, 575\u2013595 (2023).","journal-title":"Diab Metab. Syndr. Obes."},{"key":"1685_CR87","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","volume":"206","author":"A Brunchmann","year":"2019","unstructured":"Brunchmann, A., Thomsen, M. & Fink-Jensen, A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review. Physiol. Behav. 206, 232\u2013242 (2019).","journal-title":"Physiol. Behav."},{"key":"1685_CR88","doi-asserted-by":"crossref","unstructured":"Chuong, V. et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 8, e170671 (2023).","DOI":"10.1172\/jci.insight.170671"},{"key":"1685_CR89","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","volume":"45","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. Neuropsychopharmacology 45, 451\u2013461 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"1685_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cld.650","volume":"10","author":"MJ Armstrong","year":"2017","unstructured":"Armstrong, M. J. Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: from bench to bedside. Clin. Liver Dis. 10, 32\u201335 (2017).","journal-title":"Clin. Liver Dis."},{"key":"1685_CR91","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089\u20132099 (2025).","journal-title":"N. Engl. J. Med"},{"key":"1685_CR92","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 64, 399\u2013408 (2016).","journal-title":"J. Hepatol."},{"key":"1685_CR93","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski, G. et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways. JACC Basic Transl. Sci. 3, 844\u2013857 (2018).","journal-title":"JACC Basic Transl. Sci."},{"key":"1685_CR94","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 10, 155 (2019).","journal-title":"Front Endocrinol."},{"key":"1685_CR95","doi-asserted-by":"publisher","first-page":"e256637","DOI":"10.1001\/jamanetworkopen.2025.6637","volume":"8","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Detection bias in EHR-based research on clinical exposures and dementia. JAMA Netw. Open 8, e256637\u2013e256637 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1685_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75965-2","volume":"14","author":"E Kornelius","year":"2024","unstructured":"Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N. & Yang, Y.-S. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci. Rep. 14, 24433 (2024).","journal-title":"Sci. Rep."},{"key":"1685_CR97","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jpsychires.2023.05.041","volume":"164","author":"DH Cooper","year":"2023","unstructured":"Cooper, D. H. et al. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review. J. Psychiatr. Res. 164, 80\u201389 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"1685_CR98","doi-asserted-by":"publisher","first-page":"104416","DOI":"10.1016\/j.ajp.2025.104416","volume":"106","author":"Q Guo","year":"2025","unstructured":"Guo, Q., Wang, Y., Guo, L. & Shang, S. Assessing the antidepressant effects of GLP-1 receptor agonists using Mendelian randomization. Asian J. Psychiatry 106, 104416 (2025).","journal-title":"Asian J. Psychiatry"},{"key":"1685_CR99","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","volume":"32","author":"X Chen","year":"2024","unstructured":"Chen, X., Zhao, P., Wang, W., Guo, L. & Pan, Q. The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis.  Am. J. Geriatr. Psychiatry 32, 117\u2013127 (2024).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"1685_CR100","doi-asserted-by":"publisher","first-page":"T31","DOI":"10.1530\/JOE-13-0221","volume":"221","author":"C H\u00f6lscher","year":"2014","unstructured":"H\u00f6lscher, C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221, T31\u2013T41 (2014).","journal-title":"J. Endocrinol."},{"key":"1685_CR101","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/cimb47040285","volume":"47","author":"M Al Qassab","year":"2025","unstructured":"Al Qassab, M. et al. The expanding role of GLP-1 receptor agonists: advancing clinical outcomes in metabolic and mental health. Curr. Issues Mol. Biol. 47, 285 (2025).","journal-title":"Curr. Issues Mol. Biol."},{"key":"1685_CR102","doi-asserted-by":"publisher","first-page":"1525623","DOI":"10.3389\/fimmu.2025.1525623","volume":"16","author":"H Sun","year":"2025","unstructured":"Sun, H., Hao, Y., Liu, H. & Gao, F. The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment. Front. Immunol.\u00a016, 1525623 (2025).","journal-title":"Front. Immunol."},{"key":"1685_CR103","doi-asserted-by":"publisher","first-page":"e086886","DOI":"10.1136\/bmj-2025-086886","volume":"392","author":"M Cai","year":"2026","unstructured":"Cai, M., Choi, T., Xie, Y. & Al-Aly, Z. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ 392, e086886 (2026).","journal-title":"BMJ"},{"key":"1685_CR104","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951\u2013962 (2025).","journal-title":"Nat. Med."},{"key":"1685_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-21633-7","volume":"25","author":"W Li","year":"2025","unstructured":"Li, W. et al. Weighted EHR-based prevalence estimates for hypertension at the state and local levels in Louisiana. BMC Public Health 25, 432 (2025).","journal-title":"BMC Public Health"},{"key":"1685_CR106","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/jamia\/ocad115","volume":"30","author":"AD Boyd","year":"2023","unstructured":"Boyd, A. D. et al. Potential bias and lack of generalizability in electronic health record data: reflections on health equity from the National Institutes of Health Pragmatic Trials Collaboratory. J. Am. Med. Inform. Assoc. 30, 1561\u20131566 (2023).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1685_CR107","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.2196\/jmir.9134","volume":"20","author":"RA Verheij","year":"2018","unstructured":"Verheij, R. A., Curcin, V., Delaney, B. C. & McGilchrist, M. M. Possible sources of bias in primary care electronic health record data use and reuse. J. Med. Internet Res. 20, e185 (2018).","journal-title":"J. Med. Internet Res."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01685-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01685-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01685-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:02:38Z","timestamp":1791417758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01685-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01685-5","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"521"}}